StockData

aTYR PHARMA vs VivoSim Labs

ATYR and VIVS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ATYR and VIVS compare

aTYR PHARMA is the larger company, worth 1276 times as much as VivoSim Labs ($489M against $384K).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricATYRVIVS
Size and price
Market cap$489M$384K
Share price$4.99$0.120
Change, 1 year563%−94.5%
Change, 5 years−98.5%−99.8%
Beta (5Y)–2.58
Employees5815
StockData Score
Total score55
Valuation score01 (better)
Growth score00
Performance score00
Health score5 (better)4
Dividend score00
Valuation
P/S–3.4×
P/B10.0×–
FCF yield−11.2% (better)−2639%
Growth
Revenue growth (TTM)–−21.1%
Revenue growth, 5Y average−55.1%–
Profitability
Operating margin–−10117%
Net margin–−11016%
FCF margin–−9038%
Return on equity−98.4% (better)−343%
Financial health
Debt / equity0.00–
Interest coverage–−944.3×
Current ratio5.12 (better)1.70
Altman Z-score−0.96 (better)−139.28
Piotroski F-score3 (better)2
Dividends and buybacks
Buyback yield–−781%
Shareholder yield0.00% (better)−781%
Ownership
Held by institutions41.4%3.2%
Held by insiders2.6%–
Insider net buying, 12 months$43.7K (better)$2.8K
Short interest, % of float0.31%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.